Wen Di
Renji Hospital · Shanghai, China
Is this your team? Claim it
Latest publication · Nat Biomed Eng, Dec 2025A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity.
Research view
Switch to patient viewColorectal cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- TP53 6
- KRAS 57
- PD-1 108
- BRAF 36
- EGFR 32
- PD-L1 26
- PI3K 2
- STAT3 0
- CTNNB1 1
- AKT 0
- RAS 31
- HER2 38
- mTOR 1
- MAPK 1
- VEGF 14
- ERK 0
- STING 0
- NRF2 0
- PPAR 0
- CTLA-4 16
- HIF-1 0
- COX-2 5
- JNK 0
- AMPK 0
- MYC 0
- PTEN 1
- YAP 0
- GPX4 0
- NRAS 8
- IL-6 0
- JAK 0
- MET 7
- PARP 1
- CXCR4 0
- TNF 0
- NLRP3 0
- BCL-2 0
- HSP90 0
- PIK3CA 2
- GLP-1 1
- HDAC 2
- METTL3 0
- CDK4/6 2
- MEK 1
- CD47 1
- FGFR 0
- BRCA1 1
- NTRK 1
- B7-H3 5
- EZH2 0
- FAK 1
- HMGB1 0
- TROP2 4
- MUC1 2
- ATM 2
- IDO1 1
- IL-1 0
- PCSK9 3
- PINK1 0
- SHP2 0
1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD
Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)
The disease is named only in the funder's project summary, not in the title.
5 of 85 running projects, newest first. Listed amounts together: €233.2m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 133
- Organoids 108
- Mendelian Randomization Analysis 49
- CRISPR-Cas Systems 34
- Gene Expression Profiling 338
- Sequence Analysis, RNA 29
- Whole Genome Sequencing 22
- Exome Sequencing 26
- Proteomics 107
- Metabolomics 92
- Mass Spectrometry 42
- Flow Cytometry 113
- Immunohistochemistry 208
- Liquid Biopsy 36
- Circulating Tumor DNA 119
- Xenograft Model Antitumor Assays 432
- Positron-Emission Tomography 38
- Magnetic Resonance Imaging 196
- Machine Learning 211
- Deep Learning 142
- Cohort Studies 317
- Genome-Wide Association Study 65
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.